


Clopidogrel hydrogen sulfate

Cat. No.:	HY-17459
CAS No.:	120202-66-6
Molecular Formula:	C ₁₆ H ₁₈ ClNO ₆ S ₂
Molecular Weight:	420
Target:	P2Y Receptor; Cytochrome P450
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 46.7 mg/mL (111.19 mM)
 H₂O : 16.67 mg/mL (39.69 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.3810 mL	11.9048 mL	23.8095 mL
	5 mM	0.4762 mL	2.3810 mL	4.7619 mL
	10 mM	0.2381 mL	1.1905 mL	2.3810 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 50 mg/mL (119.05 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively^[1]. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation^[2]. Clopidogrel hydrogen sulfate also is an orally active P2Y₁₂ inhibitor^[5].

IC₅₀ & Target

CYP2B6 18.2 nM (IC ₅₀)	P2Y ₁₂ Receptor	CYP2C19 524 nM (IC ₅₀)
---------------------------------------	----------------------------	---------------------------------------

In Vitro

Clopidogrel (1.5 mM; 12 and 24 hours) up-regulates the expression of TRIB3 and CHOP in a concentration- and time-dependent manner, as measured by real-time PCR and Western blot analysis^[3].

Clopidogrel (1.5 mM; 24 hours) significantly induces human gastric epithelial cell (GES-1) apoptosis^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	GES-1 cells
Concentration:	1.5 mM
Incubation Time:	12 and 24 hours
Result:	The mRNA expression levels of both CHOP and TRIB3 were up-regulated in a concentration- and time-dependent manner. The protein expression levels of both CHOP and TRIB3 were up-regulated in a concentration- and time-dependent manner.

Apoptosis Analysis^[3]

Cell Line:	Gastric epithelial cell (GES-1) cells
Concentration:	1.5 mM
Incubation Time:	24 hours
Result:	Induced apoptosis of gastric epithelial cells [☒]

In Vivo

Clopidogrel (5 mg/kg) significantly inhibits thrombus formation compared with vehicle. Acetylsalicylic acid (0.15 mg/kg) can add to the antithrombotic effect of Clopidogrel in mice; Acetylsalicylic acid (0.6 mg/kg) blunts the antithrombotic effect of Clopidogrel^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Age-matched C57BL/6J male mice weighing at least 25 g were used at 8 to 12 weeks of age ^[4]
Dosage:	5 mg/kg
Administration:	Gavage treatment
Result:	Clopidogrel significantly inhibited thrombus formation compared with vehicle. When Clopidogrel was given in combination with 0.6 mg/kg ASA, thrombi were significantly larger than those measured with Clopidogrel alone. In contrast, when Clopidogrel was given in combination with 0.15 mg/kg ASA, thrombi were significantly smaller than those in mice treated with Clopidogrel and 0.6 mg/kg ASA, and smaller than those in mice given Clopidogrel alone.

CUSTOMER VALIDATION

- ACS Nano. 2023 Mar 27.
- Theranostics. 2023; 13(6):2040-2056.
- Int J Biol Sci. 2019 Jan 1;15(1):239-252.
- Thromb Res. 2023 May 8.

- Front Pharmacol. 2022 Jan 10;12:792263.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Katsunobu Hagihara, et al. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, Clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412-20.
- [2]. Jean-Marc Herbert, et al. P2Y12, a new platelet ADP receptor, target of Clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
- [3]. Hai-Lu Wu, et al. Increased endoplasmic reticulum stress response is involved in Clopidogrel-induced apoptosis of gastric epithelial cells. PLoS One. 2013 Sep 13;8(9):e74381.
- [4]. Ran Ni, et al. Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2338-2344.
- [5]. Kuszynski DS, et al. Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery [published online ahead of print, 2021 Oct 1]. Eur J Pharmacol. 2021;174545.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA